Wearables Activity Evaluator (e-Oncology)
Objective evaluation of performance status (ECOG/KPS equivalent) based on connected device data.
The Era of Medicine 2.0: Integrating Wearables in Oncology
Connected medicine, via smart Wearable Devices, marks a decisive evolution in the monitoring of oncology patients. The traditional assessment of Performance Status, relying on clinical scales such as the ECOG score or the Karnofsky index (KPS), has long been the gold standard. However, these assessments remain subjective and sporadic, offering a mere "snapshot" of the patient's condition during their medical consultation. The advent of Digital Biomarkers transforms this snapshot into a continuous "film", providing a dynamic, precise, and objective view of the patient's real vitality at home.
From Clinical Subjectivity to Objective Measurement
Smartwatches, activity trackers, and biometric sensors continuously collect massive amounts of Real-World Data (RWD). In medical oncology, these continuous parameters are invaluable to the healthcare team:
- Direct measurement of bed rest: The accelerometer accurately measures the percentage of time spent in bed or in extreme sedentariness, which is the fundamental criterion for clinically differentiating an ECOG 2 from an ECOG 3.
- Toxicity prediction: A sudden drop in the daily step count very often precedes hospitalization for severe toxicity (such as febrile neutropenia or extreme fatigue) related to chemotherapy or immunotherapy.
- Sleep monitoring and HRV: Heart Rate Variability (HRV) and sleep fragmentation are excellent invisible indicators of unreported pain or significant psychological distress.
Complementary, Not a Replacement
It is crucial to understand that connected medicine and digital biomarkers replace neither the practitioner's clinical judgment (ECOG) nor the patient's voice (PROs - Patient-Reported Outcomes). They act as a third pillar of assessment. For instance, a patient might report being "very active" (on a PRO form) out of a desire to reassure their family, while their watch indicates fewer than 2,000 steps a day. This discrepancy allows the clinician to ask better questions during the consultation and adapt the therapy accordingly.
Impact on Overall Survival and Clinical Trials
The collection of Real-World Data (RWD) is increasingly transforming Clinical Trials. Recent oncological studies demonstrate that maintaining physical activity, measured purely objectively, is directly correlated with better Overall Survival. Furthermore, early detection of biometric abnormalities via wearables enables proactive medical intervention, thereby significantly reducing emergency room admissions and improving the quality of palliative and curative care.
Correspondence: Digital Data vs Clinical Scores
| Digital Profile (Wearable) | Clinical Equivalent | Interpretation |
|---|---|---|
| High Activity (> 7000 steps/d) | ECOG 0 / KPS 90-100 | Excellent treatment tolerance. |
| Moderate Activity (3000-7000 steps/d) | ECOG 1-2 / KPS 60-80 | Moderate alert. Monitor fatigue. |
| High Sedentariness (< 2000 steps/d) | ECOG 3-4 / KPS < 50 | Physical decline. Urgent palliative evaluation. |
References:
1. Gresham G, et al. Wearable activity monitors in oncology trials: Current use of an emerging technology. JCO Clinical Cancer Informatics. 2018.
[ASCO Publications]
2. Wright AA, et al. Continuous wearable monitoring of physical activity and sleep in cancer patients. Nature Digital Medicine. 2021.
[Nature Journal]
-
💡 Committed to scientific accuracy, if you notice any clinical or technical discrepancy, please let us know.